T-cells genetically engineered to express a chimeric antigen receptor (CAR) directed against the pan B-cell marker CD19 has shown tremendous potential against hematological malignancies leading to the approval of several CD19 CAR T-cell therapies. Here, CD19 is linked to hematologic disorder.